hESC Opponents File with Supreme Court

Scientists fighting the federal funding of human embryonic stem cell research bring their case before the country’s highest court.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Wikimedia, Nissim BenvenistyIt’s been 3 years since the legality of federal funding for research involving human embryonic stem cells (hESC) was first brought to the US court system, and despite some tense moments, including a temporary ban on National Institutes of Health (NIH) funding for hESC research, the courts have continued to uphold the legality of such funding. Now, the plaintiffs are taking the final step—filing a 36-page petition, known as a writ of certiorari, with the US Supreme Court.

The petition asks the court to consider whether the federal appeals court, which ruled in support of a lower court’s finding that such funding should be allowed, was right in its assessment that such funding doesn't violate the Dickey-Wicker Amendment, which bans federal funding for any research involving the destruction of human embryos. Secondly, the researchers ask the court about the proper handling of the thousands of comments opposing hESC received by the NIH after the agency issued new guidelines in July 2009 that allowed for the submission of new hESC lines eligible for federal funding, above and beyond the 13 approved under the Bush administration, as ordered by President Barack Obama. The federal appeals court agreed that the NIH could ignore these comments, while ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies